Video

South-Central Section of the American Urological Association SCS AUA 2024 VL

Search

The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist - Cheryl Lee Details Cheryl Lee joins Zachary Klaassen to discuss the top 10 reasons why BCG as monotherapy for bladder cancer will likely cease to exist. She outlines various challenges with BCG therapy, including administration difficulties, treatment intensity, and worldwide shortages, while highlighting emerging alternatives and novel therapeutic approaches. Dr. Lee emphasizes the promise of targeted agents, impro...
High Risk Bladder Cancer Treatment Outcomes After Additional BCG - Amanda Myers Details Zachary Klaassen and Amanda Myers discuss a single-institution study examining response rates to additional BCG therapy in high-risk non-muscle invasive bladder cancer patients. Dr. Myers presents data analyzing outcomes in both BCG-exposed and BCG-unresponsive populations, providing benchmark response rates to inform clinical trial design. The study demonstrates high success rates with additional...
Real-World Treatments Following BCG Induction in Patients with NMIBC: A US Claims Analysis - Amanda Myers Details Zachary Klaassen and Amanda Myers discuss a US claims analysis examining real-world treatment patterns following BCG induction in non-muscle invasive bladder cancer patients. The study reveals significant underutilization of maintenance BCG therapy, with only a quarter of patients receiving adequate maintenance doses after induction. Their analysis highlights considerable heterogeneity in subseque...
Machine Learning Predicts Financial Toxicity in Stage IIA Non-Seminoma Treatments - Peter Sullivan Details Peter Sullivan discusses a study on financial toxicity in testicular cancer treatment. The study employs large language machine learning models and Markov modeling to predict financial toxicity patterns in stage IIA non-seminoma patients, comparing retroperitoneal lymph node dissection (RPLND) versus chemotherapy treatment approaches. Using the COST-FACIT questionnaire and a 10-year horizon analys...
36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan Details Yair Lotan joins Zachary Klaassen to discuss the 36-month follow-up data of nadofaragene firadenovec for BCG-unresponsive bladder cancer. The phase 3 trial evaluates the long-term efficacy and safety of nadofaragene, an intravesical adenovirus vector administered every three months, in patients with carcinoma in situ and papillary disease. While initial response rates are promising, the discussion...
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah Details Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes). The study examines the real-world impact of blue light cystoscopy versus white light cystoscopy in non-muscle invasive bladder cancer patients within the VA healthcare system. Using data from 1997 to 2021, the research demonstrates significantly reduced recurrence rates at three years with blue l...
Challenges in Transitioning Men from Active Surveillance to Watchful Waiting - Lisa Lowenstein Details Zachary Klaassen speaks with Lisa Lowenstein about transitioning men from active surveillance to watchful waiting in prostate cancer management. Dr. Lowenstein shares insights from her research on patient and clinician perspectives, highlighting the challenges of convincing men to reduce their monitoring intensity. She describes developing a shared decision-making intervention to help guide these...